LOCATIONS: NEW YORK CITY | LONG ISLAND
BOOK YOUR CONSULTATION NOW: 917-261-7370
SPRAVATO® (esketamine) is an FDA-approved nasal spray treatment for adults with treatment-resistant depression. New York Ketamine Infusions provides medically supervised SPRAVATO® treatment at our Lower Manhattan clinic for eligible patients throughout New York City.
If antidepressants have not provided enough relief, our clinical team can help determine whether SPRAVATO® may be appropriate and help you understand your insurance coverage.
SPRAVATO® is the brand name for esketamine, an FDA-approved prescription nasal spray for adults with treatment-resistant depression. Treatment takes place in a certified healthcare setting under medical supervision. Patients self-administer the nasal spray and are monitored for at least two hours after treatment.
160 Broadway, 16th Floor
New York, NY 10038
SPRAVATO® is FDA-approved for adults with treatment-resistant depression.
Many commercial, Medicare and Medicaid plans may provide coverage for eligible patients.
Treatment is administered in-office with required medical observation afterward.
Treatment-resistant depression generally describes depression that has not improved adequately after appropriate antidepressant treatment. For some people, symptoms continue despite trying more than one medication.
SPRAVATO® offers a different treatment approach. Rather than primarily targeting serotonin or norepinephrine pathways, esketamine acts on the NMDA/glutamate system.
New York Ketamine Infusions provides medically supervised SPRAVATO® treatment for eligible adults with treatment-resistant depression.
Esketamine works differently from conventional antidepressants. SPRAVATO® is an NMDA receptor antagonist associated with modulation of glutamate signaling, an important communication system in the brain.
Esketamine acts primarily through NMDA and glutamate pathways rather than relying solely on the neurotransmitter systems targeted by many traditional antidepressants.
SPRAVATO® has been specifically studied in adults whose depression has not responded adequately to previous antidepressant treatment.
Treatment response varies. Your clinical team monitors symptoms, tolerability and progress to determine whether continued treatment is appropriate.
Your healthcare team reviews relevant health information and checks your blood pressure before treatment.
You self-administer SPRAVATO® nasal spray under the direct observation of a healthcare professional.
You remain at the healthcare setting for at least two hours after administration so your clinical team can monitor you.
Patients need to arrange transportation home and should not drive until the following day after a restful sleep.
Treatment generally begins more frequently and can become less frequent as treatment progresses. Your provider determines the appropriate schedule based on clinical response and individual need.
Typically twice weekly
Typically once weekly
Weekly or every 2 weeks based on clinical need
Treatment schedules are individualized. Your provider determines dosing frequency and whether continued treatment is appropriate.
SPRAVATO® and IV ketamine are related treatments, but they are not the same medication and are administered differently.
SPRAVATO® contains esketamine and is administered as a nasal spray. IV ketamine uses racemic ketamine administered intravenously.
Insurance coverage can also differ. SPRAVATO® is FDA-approved for specific depression indications and may be covered by insurance for eligible patients, while IV ketamine for depression is an off-label treatment and is often paid out of pocket.
Compare Ketamine vs. SPRAVATO® in New York CityEsketamine nasal spray • FDA-approved for specific depression indications • In-office administration • Insurance coverage may be available.
Racemic ketamine • Intravenous administration • Used off-label for depression • Often self-pay for psychiatric treatment.
Many health insurance plans may cover SPRAVATO® for eligible patients with treatment-resistant depression. Coverage depends on your specific plan, diagnosis, treatment history, medical necessity and authorization requirements.
Our team can help you understand SPRAVATO® insurance coverage in New York, verify benefits and explain the authorization process before treatment.
New York Ketamine Infusions accepts many commercial, Medicare, Medicaid, military, employer-sponsored, and behavioral health insurance plans for eligible SPRAVATO® patients.
Insurance participation and coverage vary by individual plan, medical necessity, prior authorization requirements, and eligibility. If you don't see your insurance listed, contact our team—we're happy to verify your benefits and determine whether SPRAVATO® treatment may be covered.
New York Ketamine Infusions provides SPRAVATO® treatment at 160 Broadway, 16th Floor, New York, NY 10038.
Our Lower Manhattan location serves patients living and working throughout the Financial District, Tribeca, SoHo, Chinatown, Battery Park City, Lower East Side, Greenwich Village, West Village, Chelsea and surrounding New York City communities.
Because SPRAVATO® requires post-treatment observation and patients cannot drive home afterward, location and transportation are practical considerations when choosing a treatment center.
Learn more about SPRAVATO® treatment at New York Ketamine Infusions →
160 Broadway, 16th Floor
New York, NY 10038
Phone: 917-261-7370
Treatment Hours:
7 days a week: 9 AM–7 PM
Take the next step toward care. Contact New York Ketamine Infusions to schedule an appointment and learn more about insurance-covered depression treatment in Manhattan and New York City.
SPRAVATO® may be appropriate for certain adults with treatment-resistant depression. A clinical evaluation is required to review diagnosis, previous antidepressant treatment, current medications, medical history and potential contraindications.
Many commercial insurance, Medicare and Medicaid plans may cover SPRAVATO® for eligible patients. Coverage depends on the specific plan, medical necessity, treatment history and authorization requirements. Learn more about SPRAVATO® insurance coverage.
New York Medicaid coverage may be available for eligible patients depending on the applicable plan, clinical criteria and authorization requirements. Read our guide to Medicaid coverage for SPRAVATO® in New York.
No. SPRAVATO® must be self-administered under direct observation in a certified healthcare setting. Patients are monitored for at least two hours after administration.
Patients need to arrange transportation after treatment and should not drive or perform activities requiring full alertness until the following day after a restful sleep.
No. SPRAVATO® contains esketamine and is administered as a nasal spray. IV ketamine uses racemic ketamine and is administered intravenously. See our detailed ketamine vs. SPRAVATO® comparison for New York City.
Patients must be monitored for at least two hours after administration, in addition to time needed for preparation, administration and clinical assessment.
Start with a clinical consultation. New York Ketamine Infusions can review your treatment history, determine whether SPRAVATO® may be clinically appropriate and help investigate your insurance benefits.
A consultation can help determine whether SPRAVATO® may be appropriate for your treatment history and whether your insurance plan may provide coverage.
Request Your Consultation